Tibet Rhodiola Pharmaceutical Holding Co (600211) - Total Liabilities
Based on the latest financial reports, Tibet Rhodiola Pharmaceutical Holding Co (600211) has total liabilities worth CN¥2.16 Billion CNY (≈ $316.67 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Tibet Rhodiola Pharmaceutical Holding Co to see how much of total assets are deployed in long-term investments.
Tibet Rhodiola Pharmaceutical Holding Co - Total Liabilities Trend (1996–2025)
This chart illustrates how Tibet Rhodiola Pharmaceutical Holding Co's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Tibet Rhodiola Pharmaceutical Holding Co total assets.
Tibet Rhodiola Pharmaceutical Holding Co Competitors by Total Liabilities
The table below lists competitors of Tibet Rhodiola Pharmaceutical Holding Co ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Evertec Inc
NYSE:EVTC
|
USA | $1.76 Billion |
|
NCAB Group
ST:NCAB
|
Sweden | Skr2.08 Billion |
|
Shenzhen Bluetrum Technology Co. Ltd. A
SHG:688332
|
China | CN¥630.58 Million |
|
Bob's Discount Furniture, Inc.
NYSE:BOBS
|
USA | $815.06 Million |
|
Charter Hall Long Wale REIT
AU:CLW
|
Australia | AU$2.01 Billion |
|
Sildarvinnslan Hf.
IC:SVN
|
Iceland | Ikr388.55 Million |
|
Cury Construtora e Incorporadora S.A
SA:CURY3
|
Brazil | R$3.99 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Tibet Rhodiola Pharmaceutical Holding Co's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600211 net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tibet Rhodiola Pharmaceutical Holding Co's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tibet Rhodiola Pharmaceutical Holding Co (1996–2025)
The table below shows the annual total liabilities of Tibet Rhodiola Pharmaceutical Holding Co from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥2.10 Billion ≈ $307.56 Million |
+164.30% |
| 2024-12-31 | CN¥795.23 Million ≈ $116.37 Million |
-34.48% |
| 2023-12-31 | CN¥1.21 Billion ≈ $177.61 Million |
+13.58% |
| 2022-12-31 | CN¥1.07 Billion ≈ $156.38 Million |
-7.69% |
| 2021-12-31 | CN¥1.16 Billion ≈ $169.40 Million |
+225.26% |
| 2020-12-31 | CN¥355.91 Million ≈ $52.08 Million |
+11.07% |
| 2019-12-31 | CN¥320.44 Million ≈ $46.89 Million |
+16.57% |
| 2018-12-31 | CN¥274.89 Million ≈ $40.23 Million |
-3.42% |
| 2017-12-31 | CN¥284.64 Million ≈ $41.65 Million |
-82.56% |
| 2016-12-31 | CN¥1.63 Billion ≈ $238.88 Million |
+640.59% |
| 2015-12-31 | CN¥220.43 Million ≈ $32.26 Million |
-65.14% |
| 2014-12-31 | CN¥632.26 Million ≈ $92.52 Million |
-14.36% |
| 2013-12-31 | CN¥738.26 Million ≈ $108.03 Million |
+60.59% |
| 2012-12-31 | CN¥459.72 Million ≈ $67.27 Million |
+6.19% |
| 2011-12-31 | CN¥432.93 Million ≈ $63.35 Million |
+5.26% |
| 2010-12-31 | CN¥411.28 Million ≈ $60.18 Million |
-7.31% |
| 2009-12-31 | CN¥443.70 Million ≈ $64.93 Million |
-19.40% |
| 2008-12-31 | CN¥550.51 Million ≈ $80.56 Million |
-1.29% |
| 2007-12-31 | CN¥557.68 Million ≈ $81.61 Million |
+18.51% |
| 2006-12-31 | CN¥470.56 Million ≈ $68.86 Million |
+10.11% |
| 2005-12-31 | CN¥427.37 Million ≈ $62.54 Million |
+25.06% |
| 2004-12-31 | CN¥341.74 Million ≈ $50.01 Million |
+3.61% |
| 2003-12-31 | CN¥329.82 Million ≈ $48.26 Million |
+4.96% |
| 2002-12-31 | CN¥314.23 Million ≈ $45.98 Million |
+55.70% |
| 2001-12-31 | CN¥201.82 Million ≈ $29.53 Million |
+60.16% |
| 2000-12-31 | CN¥126.01 Million ≈ $18.44 Million |
+169.65% |
| 1999-12-31 | CN¥46.73 Million ≈ $6.84 Million |
-34.80% |
| 1998-12-31 | CN¥71.68 Million ≈ $10.49 Million |
+108.83% |
| 1997-12-31 | CN¥34.32 Million ≈ $5.02 Million |
+17.23% |
| 1996-12-31 | CN¥29.28 Million ≈ $4.28 Million |
-- |
About Tibet Rhodiola Pharmaceutical Holding Co
Tibet Rhodiola Pharmaceutical Holding Co. produces and sells pharmaceutical products in China and internationally. The company offers modern Tibetan Medicines, including Nodikang capsules and granules, snow mountain golden arhat pain relief film, and ten-flavor Tida capsules; modern Chinese medicines, such as children Shuangqing granules, lipid clearing capsules, ginseng and zhi capsules, puyu ca… Read more